Artist Jacob van der Beugel will be working with ECSG to produce a wall relief installation using ceramics and concrete. His work will embrace the metaphor of concrete cancer.
Jacob's work is part of the larger Artist in Residence Scheme, funded by the University's Centre for Chronic Diseases and Dirsorders (C2D2) to produce a body of work inspired by research in biomedicine and human health.
Read more about the scheme via C2D2's website.
The online news coverage of the research on a number of US radio stations suggests that taller adults are more likely to develop cancer than shorter men and women.
Eve, Director of the Epidemiology and Cancer Statistics Group, commented that the association between height and cancer is old news. “Although it seems from the information available that the study is likely to be robust and has been done resonably well, as far as I can see this study contributes little that is new.”
Read more on WSFA.
A new project by HMRN researchers, in collaboration with the NHS and 14m Genomics, will analyse samples from over 20,000 haematological cancer patients to identify how differences in their cancer cells' DNA can influence the success of treatment. The collaboration announced today will search for patterns that can inform doctors and patients about prognosis. Read more.
Acute myeloid leukaemia (AML) is an aggressive cancer, with treatments ranging from supportive care (mainly blood product transfusion) to intensive chemotherapy and stem cell transplantation. A team of researchers at the University of York recently addressed these issues by developing a hybrid model combining a decision tree with several Markov models. Read full news piece (MS Word , 18kb).
Scientists from Health Sciences at the University of York, in collaboration with colleagues at the University of Leeds and clinical partners at St James’s Institute of Oncology, have been awarded £250k to develop a novel approach for determining the best treatment for patients suffering from haematological malignancies (leukaemias, lymphomas and myeloma). Read more.
Patients from less affluent backgrounds have a greater chance of dying from a form of chronic blood cancer than those from more affluent areas, according to a comprehensive study carried out by researchers at the University of York. Read more.
Dr Alex Smith will be representing ECSG at The American Society of Hematology (ASH) conference and presenting posters entitled: Bone Marrow Staging For Lymphoma, Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia, and Skeletal-Related Events In Myeloma. See www.hematology.org/meetings/annual-meeting/ for more information.
Department of Health Sciences researchers and their clinical NHS colleagues are expanding a project to investigate the health and well-being of newborn babies and their parents, to include a study of depression during pregnancy and early motherhood. Read more.
Congratulations to John Blase who has recently been awarded an MA in Online and Distance Education by the Open University. The degree is part of a programme that comprises a postgraduate certificate and diploma. The course explored in depth the research and practice literature in technology-enhanced forms of learning, through the study of innovations such as open educational resources and focusing on the development of all-inclusive practices with regard to the online accessibility of learning materials for all stakeholders, including thoses with disabilities. This degree is the culmination of John's work for a number of years providing pedagogical and technical support for ECSG's online distance MSc course in Haematopathology, as well as contributing to the dissemination of the group's research findings through project websites, study documentation literature and patient information materials.
Congratulations to Simon Crouch, who has received part of £1m funding from the Leukaemia and Lymphoma Research charity to investigate why some patients with diffuse large B-cell lymphoma (DLBCL) fail to respond to standard treatment. The five-year collaborative project between researchers at the University of York, the Haematological Malignancy Diagnostic Service (HDMS) at Leeds Teaching Hospitals NHS Trust, and the Universities of Cambridge and Southampton aims to have targetted and more effective treatment options for patients with blood cancers. Read more.
On May 18th, the Epidemiology & Cancer Statistics Group along with their major funder, the Leukaemia & Lymphoma Research charity, hosted an open day for patients with blood disorders plus their families, friends and carers. The reception, which aimed to raise awareness about the research taking place in the area, was held at the Ron Cooke Hub and attracted more than 170 visitors. The main focus of the event was a celebration of the Yorkshire and Humberside Haematology Network, or Haematological Malignancy Research Network as it is better known to the research community. Read more.
Congratulations to Alex Smith, who has been successful in gaining a renewal of funding for CellBank, a project that oversees national banking of samples from children diagnosed with leukaemia across the UK to a centralised laboratory. These samples will aid research into pathogenesis, treatment response and outcome.
On May 10th 2013, the University of York’s Epidemiology & Cancer Statistics Group, in its role as major founding partner of the Haematological Malignancy Research Network (www.hmrn.org), successfully hosted the B-cell malignancies: the impact of biomarkers on treatment decisions single-day conference. The event was held at the National Science Learning Centre and organised in association with the Lunenburg Lymphoma Biomarker Consortium, an international initiative studying the application of biomarker analyses to clinical practice in lymphoma. Attended by over 90 delegates from a range of academic, clinical, pharmaceutical and biomedical backgrounds, the conference talks included mutually complementary contributions on all aspects of the pathogenesis and treatment of B-cell malignancies, both in a clinical pathway relevant context (diagnosis to prognosis to patient management and follow-up) and from a research-focused point of view (the application of novel bioinformatics concepts, development of stratified medicine-based clinical trials, integration of biomarkers onto large-scale population-based data).
The conference had been approved by the Royal College of Pathologists for 5 CPD Credits and initial feedback responses from the delegates have been very good, commenting both on the quality and breadth of the presentations and on the excellence of the venue and its resources. Immediate follow-up plans involve the dissemination of the presentations to the wider public through HTML5 video files available through the conference website (www.biomarkerconf.co.uk).
The event was part-funded by the Wellcome Trust (Centre for Chronic Diseases and Disorders – ref: 097829/Z/11/A) and Roche.